Summary A retrospective analysis of 108 cases of primary germ cell tumours of testis seen over a 6 year
Testicular tumours account for only about 1% of all cancers but are the most common neoplasms in the 15-35 year old age group . This cancer thus has the potential of resulting in the loss of productive years of life. With the advent of modern chemotherapeutic agents most importantly DDP, testicular cancers have become largely curable. Although the natural history of this neoplasm is well known in the west, its natural history in India which currently has a population of about 850 million is not well documented. The aim of this paper is to put on record the clinical features, treatment and problems of management of 108 cases of primary germ cell tumours of testis that were seen over a 6 year period at Institute Rotary Cancer Hospital (IRCH) of All India Institute of Medical Sciences (AIIMS) New Delhi. This is a regional cancer centre and gets referrals from north and north central India involving 50 million, a population almost equal to that of UK.
Materials and methods
Case records of all patients with testicular tumours that were registered at IRCH between Jan 1985 and Dec 1990 were analysed. These patients had a proven histological diagnosis, a complete clinical examination and staging. One hundred and thirteen cases of primary testicular tumours were registered. Five of these patients had non germ cell tumours and have been excluded from analysis. Besides clinical examination, all patients had complete hemogram, routine biochemistry, markers like b-human chorionic gonadotrophin and alpha fetoprotein, radiograph of the chest, and CT scans. Patients were staged using the Royal Marsden Hospital classification (Peckham et al., 1979) . Histological staging was done using the WHO classification (Mostofi & Sobin, 1977 Survival in months Figure 1 Probability of survival seminoma (stages II-IV) 16 pts. There were no deaths in stage I in either group. Some patients stopped coming for follow up even after completing their treatment. We therefore calculated the probability of survival. The data for the group as a whole is provided in Figure 5 . (Grover et al., 1985) . Testicular tumours form about 1% of all tumours registered at IRCH. Population surveys indicate a crude incidence rate of 0.7 to 1 per 100,000 persons at Banglore, Bombay and Madras, the three centres from where information is available (Annual Report 1987, National Cancer Registry Programme, New Delhi). As population surveys from the rest of the country are not available the exact incidence of this disease is not known. Based on the rates of incidence from other major cities in India, it was expected that at least 350 new cases would be diagnosed every year. For the last 2 years i.e. 1990 and 1991 we have been registering about 60 cases every year which is slightly less than 20% of all possible new cases occurring in the population. It is obvious that all patients are not seen at our center. This could be either because they are not diag- (Peckham et al., 1979) . Tumours in undescended testis formed a proportion that is much higher than the current western figures and reflects the underdeveloped health services in peripheral areas (Einhorn et al., 1979) . All patients who had tumours on undescended or maldescended testis had received either no or very poor primary education and belonged to very poor socio-economic class. Majority of such cases underwent laparotomy for diagnosis (14 out of 15). Resection in most of these cases was incomplete and patients required either chemotherapy or radiotherapy. This practice has changed over the last 2 years. Whenever this condition is suspected now (any abdominal mass with absent scrotal testes) tumour markers i.e. B-HCG and AFP are done, and histopathology obtained by tru-cut needle. If germ cell tumour is diagnosed, the patient is given appropriate chemotherapy and surgery reserved only for resistant residual masses or removal of intraabdominal testis. With the availability of reliable markers and investigation facilities like whole body CT scanning and ultrasound the management of testicular tumours has become more rational Our main problems remain the (i) management of bulky disease, (ii) inability of patients to take complete treatment (iii) loss of follow up even in those who have become asymptomatic after initial treatment or have completed the prescribed treatment. This is particularly unfortunate for a potentially curable cancer like that of testis. The reasons are poverty, low education of patients and distances that they have to travel to because of the paucity of good cancer centres. The inability to take complete treatment is particularly great for patients with stage II bulky, III & IV. This is obviously because of the vast majority require chemotherapy which is expensive. Some of these patients return home without even informing us. We attempted to contact these patients by means of reply paid letters but the response was only 36%. This situation needs to be improved because testicular tumour patients are curable even in advanced stage. Our policy in stage I NSGCT is surveillance. This however may not be universally appropriate for our conditions, as surveillance presumes that the follow up be strict. Three of our patients on surveillance were lost to follow up. Also the cost of surveillance may be prohibitive in terms of frequent visits to hospital and need for regular CT scanning. CT scan and ultrasound facilities are available only in major hospitals in the cities. In such patients where it is feared that follow up may not be adequate, giving adjuvant chemotherapy or radiotherapy may be a good alternate option. This approach may be wholly appropriate for a certain section of our population and is currently being debated in our department. We do not currently favour retroperitoneal lymph node dissection for stage I NSGCT partly because of its significant morbidity in terms of failure of ejaculation which can become a major problem in young sexually active males and partly because it is difficult to convince asymptomatic patients to undergo major surgery. The current policy is to stratify patients into low, intermediate and high volume disease and to offer chemotherapy appropriate to the stage and volume as is practised by EORTC.
